Skip to content
HowShorted

Atara Biotherapeutics, Inc. short interest in 2022

In 2022, Atara Biotherapeutics, Inc.'s disclosed short interest ran from 6.72% of shares outstanding on 14 Jan 2022 to 13.71% on 30 Dec 2022, a change of +6.99 percentage points. The year's high was 13.71% on 30 Dec 2022 and its low 6.72% on 14 Jan 2022, averaging 11.34% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.30 days on 29 Apr 2022. Full history: Atara Biotherapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Atara Biotherapeutics, Inc. in 2022

2022 in figures

Start of year
6.72% (14 Jan 2022)
End of year
13.71% (30 Dec 2022)
Change
+6.99 pp
High
13.71% (30 Dec 2022)
Low
6.72% (14 Jan 2022)
Average
11.34%
Highest days to cover
14.30 (29 Apr 2022)
SEC filings marked
9

Every report in 2022

Atara Biotherapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20226.72%6.46
31 Jan 20227.88%6.85results (8-K)
15 Feb 20227.99%10.46
28 Feb 20228.20%8.9310-K filed, results (8-K)
15 Mar 20229.88%6.47
31 Mar 202211.00%8.92
14 Apr 202212.57%11.06
29 Apr 202212.63%14.30
13 May 202211.80%9.0510-Q filed, results (8-K)
31 May 202212.56%9.96
15 Jun 202212.07%10.71
30 Jun 202211.46%6.65
15 Jul 20228.61%2.43
29 Jul 202211.17%3.17
15 Aug 202211.95%2.8310-Q filed, results (8-K)
31 Aug 202211.88%6.88
15 Sep 202213.08%6.79
30 Sep 202213.05%5.93
14 Oct 202212.61%9.71
31 Oct 202212.63%9.66
15 Nov 202212.70%7.5810-Q filed, results (8-K)
30 Nov 202212.91%11.95
15 Dec 202213.06%8.94
30 Dec 202213.71%5.97

See also: Atara Biotherapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.